Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:C-terminal amino-acid residue
go back to main search page
Accession:CHEBI:33711 term browser browse the term
Definition:The residue in a peptide that has a free carboxyl group, or at least does not acylate another amino-acid residue, is called C-terminal.
Synonyms:exact_synonym: C-terminal residue
 related_synonym: C-terminal amino-acid residues;   carboxyl-terminal residue


show annotations for term's descendants           Sort by:
lisinopril dihydrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity ISO Lisinopril analog results in decreased activity of ACE protein CTD PMID:22200082 NCBI chr11:105,858,774...105,880,790
Ensembl chr11:105,858,771...105,880,790 		JBrowse link
G Ace2 angiotensin converting enzyme 2 increases activity
increases expression
multiple interactions		 ISO
EXP		 Lisinopril results in increased activity of ACE2 protein
Lisinopril results in increased expression of ACE2 mRNA
ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]		 CTD PMID:15897343 PMID:16221218 PMID:27649628 NCBI chr  X:162,922,338...162,971,414
Ensembl chr  X:162,922,328...162,971,416 		JBrowse link
G Ache acetylcholinesterase multiple interactions EXP
ISO		 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]
Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein]		 CTD PMID:23060470 PMID:31710167 NCBI chr 5:137,286,516...137,292,728
Ensembl chr 5:137,285,781...137,292,728 		JBrowse link
G Agt angiotensinogen decreases expression
increases expression
affects response to substance
decreases secretion
increases secretion
multiple interactions
affects metabolic processing		 ISO
EXP		 Lisinopril results in decreased expression of AGT protein
Lisinopril results in increased expression of AGT mRNA
AGT gene alternative form affects the susceptibility to Lisinopril
Lisinopril results in decreased secretion of AGT protein
Lisinopril results in increased secretion of AGT protein alternative form
[Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA
[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)]
[[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein		 CTD PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 More... NCBI chr 8:125,283,326...125,296,445
Ensembl chr 8:125,283,273...125,296,445 		JBrowse link
G Bcl2 B cell leukemia/lymphoma 2 decreases expression ISO Lisinopril results in decreased expression of BCL2 CTD PMID:10075388 NCBI chr 1:106,465,906...106,642,020
Ensembl chr 1:106,465,908...106,642,004 		JBrowse link
G Cd2ap CD2-associated protein multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein] CTD PMID:16636307 NCBI chr17:43,059,857...43,187,593
Ensembl chr17:43,103,842...43,187,556 		JBrowse link
G Edn1 endothelin 1 decreases secretion ISO Lisinopril results in decreased secretion of EDN1 protein CTD PMID:19079593 NCBI chr13:42,454,952...42,461,466
Ensembl chr13:42,454,952...42,461,466 		JBrowse link
G Gh growth hormone multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr11:106,191,087...106,194,529
Ensembl chr11:106,191,097...106,192,691 		JBrowse link
G H2-M3 histocompatibility 2, M region locus 3 affects expression ISO Lisinopril affects the expression of HLA-G mRNA CTD PMID:25811541 NCBI chr17:37,581,094...37,585,380
Ensembl chr17:37,581,111...37,585,375 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] CTD PMID:19225054 NCBI chr11:46,630,644...46,670,405
Ensembl chr11:46,625,907...46,670,405 		JBrowse link
G Hpse heparanase multiple interactions ISO [Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein] CTD PMID:19429930 NCBI chr 5:100,827,350...100,867,582
Ensembl chr 5:100,827,350...100,867,582 		JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression ISO Lisinopril results in increased expression of IGFBP1 protein CTD PMID:9663927 NCBI chr11:7,147,787...7,152,546
Ensembl chr11:7,147,782...7,152,546 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] CTD PMID:20051877 NCBI chr 8:93,553,920...93,580,049
Ensembl chr 8:93,553,919...93,580,048 		JBrowse link
G Mpo myeloperoxidase multiple interactions EXP 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein] CTD PMID:23060470 NCBI chr11:87,684,610...87,695,238
Ensembl chr11:87,684,407...87,695,239 		JBrowse link
G Nos2 nitric oxide synthase 2, inducible multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] CTD PMID:20051877 NCBI chr11:78,811,613...78,851,052
Ensembl chr11:78,811,613...78,851,080 		JBrowse link
G Nphs2 nephrosis 2, podocin multiple interactions ISO Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein] CTD PMID:16636307 NCBI chr 1:156,138,105...156,155,605
Ensembl chr 1:156,138,297...156,155,605 		JBrowse link
G Nppa natriuretic peptide type A decreases expression ISO Lisinopril results in decreased expression of NPPA protein CTD PMID:8393685 NCBI chr 4:148,085,179...148,086,531
Ensembl chr 4:148,085,179...148,086,536 		JBrowse link
G Ren1 renin 1 structural increases expression
multiple interactions		 ISO Lisinopril results in increased expression of REN protein
Lisinopril results in increased expression of REN mRNA
[Lisinopril co-treated with Losartan] results in increased expression of REN mRNA		 CTD PMID:2550029 PMID:8915971 PMID:16221218 NCBI chr 1:133,278,412...133,288,058
Ensembl chr 1:133,278,248...133,288,063 		JBrowse link
G Spmip11 sperm microtubule inner protein 11 multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein] CTD PMID:16636307 PMID:19293598 NCBI chr15:98,468,885...98,487,469
Ensembl chr15:98,468,885...98,487,461 		JBrowse link
G Timp1 tissue inhibitor of metalloproteinase 1 multiple interactions ISO [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] CTD PMID:20051877 NCBI chr  X:20,736,524...20,740,972
Ensembl chr  X:20,736,405...20,740,974 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein] CTD PMID:19293598 NCBI chr17:46,327,919...46,343,303
Ensembl chr17:46,327,919...46,343,295 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 22194
    chemical entity 22193
      group 22088
        organic group 20308
          amino-acid residue 11233
            C-terminal amino-acid residue 21
              C-terminal L-alpha-amino-acyl-L-glutamyl-L-glutamyl-L-phenylalanine(3-) residue 0
              C-terminal alpha-amino-acid residue + 21
              C-terminal alpha-amino-acyl-L-glutamate(2-) residue 0
              C-terminal alpha-amino-acyl-L-glutamyl-L-glutamate(2-) residue 0
              C-terminal alpha-amino-acyl-L-glutamyl-L-glutamyl-L-tyrosinate(3-) residue 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 22194
    subatomic particle 22186
      composite particle 22186
        hadron 22186
          baryon 22186
            nucleon 22186
              atomic nucleus 22186
                atom 22186
                  main group element atom 22120
                    main group molecular entity 22120
                      s-block molecular entity 21717
                        hydrogen molecular entity 21634
                          hydrides 20777
                            inorganic hydride 18692
                              pnictogen hydride 18672
                                nitrogen hydride 18540
                                  azane 18447
                                    ammonia 18446
                                      organic amino compound 18446
                                        amino acid 16431
                                          amino-acid residue 11233
                                            C-terminal amino-acid residue 21
                                              C-terminal L-alpha-amino-acyl-L-glutamyl-L-glutamyl-L-phenylalanine(3-) residue 0
                                              C-terminal alpha-amino-acid residue + 21
                                              C-terminal alpha-amino-acyl-L-glutamate(2-) residue 0
                                              C-terminal alpha-amino-acyl-L-glutamyl-L-glutamate(2-) residue 0
                                              C-terminal alpha-amino-acyl-L-glutamyl-L-glutamyl-L-tyrosinate(3-) residue 0
paths to the root